Related Experiment Video

Updated: Apr 17, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.9K

Improving evidence developed from population-level experience with targeted agents

M B McClellan1, G W Daniel, D Dickson

  • 1The Brookings Institution, Washington, DC, USA.

Clinical Pharmacology and Therapeutics
|February 14, 2015
PubMed

Insights

Off-label drug use in cancer care is common but lacks outcome data. Developing oncology patient registries can improve evidence for targeted therapies used in new settings.

Area of Science:

  • Oncology
  • Pharmacology
  • Biostatistics

Background:

  • Off-label drug prescribing is prevalent in oncology, driven by unmet medical needs and rare cancers.
  • Targeted anti-cancer agents may show efficacy across tumor types with shared genomic biomarkers.
  • Current off-label prescribing practices do not systematically capture patient outcomes.

Purpose of the Study:

  • To explore methods for collecting patient outcome data for off-label drug use in oncology.
  • To propose solutions for enhancing evidence development around targeted therapies used in new indications.
  • To highlight the importance of patient registries in validating off-label prescribing.

Main Methods:

  • Review of current practices in off-label oncology drug prescribing.
  • Exploration of data collection strategies for patient outcomes.
  • Presentation of two proposals for oncology-specific patient registries.

Main Results:

  • Off-label use of targeted therapies is scientifically plausible but lacks robust outcome data.
  • Patient registries offer a viable mechanism for collecting real-world evidence on off-label drug efficacy and safety.
  • Key considerations for registry implementation include data standardization and ethical oversight.

Conclusions:

  • Systematic data collection through patient registries is crucial for validating off-label targeted therapy use.
  • Improved evidence development can optimize patient care and drug utilization in oncology.
  • Future efforts should focus on establishing robust data infrastructure for off-label oncology drug use.
Keywords:
Clinical Pharmacology & TherapeuticsMonth YearVolume X Number Y

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.2K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
955
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
392